Medacta Group SA · SIX:MOVE
Medacta Group SA — H1 2019 Earnings Presentation
25 slides from Medacta Group SA's earnings presentation, Sep 3, 2019
Slide 1: 1H 2019 Financial results
1H 2019 Financial results 3rd September 2019 PATIENT WELL-BEING MEDICAL EDUCATION INNOVATION 1
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the Medacta Half Year 2019 Report ava
Slide 3: Agenda
Agenda ▪ Business update ▪ 1H 2019 results ▪ Outlook 3
Slide 4: Medacta expands further achieving strong revenue growth and profitability
Medacta expands further achieving strong revenue growth and profitability Sales growth in all regions and business lines ▪ Revenues up by 13.8% to €151.6 million (+11.0% in CC1) ▪ Growth significantly above the market ▪ Adjusted and Normalized EBITDA margin of 31.0% (2) ▪ Substantial progress in the
Slide 5: Business update
Adedacta International Business update
Slide 6: An international high-growth platform with a new approach to orthopedics
An international high-growth platform with a new approach to orthopedics 1 2 3 4 5 High-growth Differentiated Dedicated Rich pipeline of Experienced and orthopedics company minimally invasive surgeon education innovation-led committed leadership with and personalized program offerings team internati
Slide 7: Sales growth in all regions and business lines
Sales growth in all regions and business lines: Revenues up by 13.8% to €151.6 million (+11.0% in CC) Growth by regions (%)1 Growth by products (%)1 Commentary ▪ Recorded strong organic growth in the first half of 2019 and Medacta sales increased by 13.8% compared to the RoW 18.2% Spine 11.1% same p
Slide 8: Regional segments 1H 2019 vs 1H 2018
Regional segments 1H 2019 vs 1H 2018 Revenue by regions (€m)1 Commentary Growth % ▪ In Europe, the largest region in terms of revenue, sales increased by 8.2% to 147.9 +18.2% €70.0 million, in line with last year’s 5.4 133.3 growth 4.6 30.2 +7.6% ▪ The growth in the US was particularly 28.1 high des
Slide 9: Business segments 1H 2019 vs 1H 2018
Business segments 1H 2019 vs 1H 2018 Revenue by products (€m)1 Commentary Growth % ▪ Revenue growth above market averages across all business lines 147.9 +11.1% ▪ In Hip, the AMIS approach continued to 133.3 10.5 4.0 +171.3% drive growth due to better operating 9.5 1.5 room efficiency, better accura
Slide 10: Impactful Lugano Congress highlights Medacta's innovation leadership
Impactful Lugano Congress highlights Medacta’s innovation leadership 9th M.O.R.E. international symposium ▪ Focus on the growing trend of personalized medicine and the impact of customizable tools and patient-matched solutions in various orthopedic disciplines ▪ 1,500 attendees, 900 orthopedic surge
Slide 11: MySpine MIS Midline Cortical Platform awarded Best Healthcare Navigation / Robotics Solution
MySpine MIS Midline Cortical (MC) Platform awarded Best Healthcare Navigation / Robotics Solution Next generation healthcare navigation and robotics solution ▪ MedTech Breakthrough Awards recognize game-changing technologies throughout the medical industry ▪ MySpine MIS1 MC is a minimally invasive,
Slide 12: Sustained growth of the shoulder business underlined by the launch of new products
Sustained growth of the shoulder business underlined by the launch of new products Medacta Shoulder System: An innovative modular shoulder replacement system ▪ Successfully rolled out the Medacta Shoulder System in the US, Australia and Japan ▪ Continued introduction of key technologies across globa
Slide 13: 1H 2019 Financial performance
1H 2019 Financial performance 13
Slide 14: Key figures 1H 2019
Key figures 1H 2019 Adjusted and Norm.(1) Revenue (€m) Gross profit (€m) EBITDA (€m) 151.6 111.6 47.0 Adjusted and Norm. (1) Adjusted and Norm. (1) Revenue growth EBITDA growth EBITDA margin +13.8% +8.8% 31.0% +11.0% cc Notes: 1. For a reconciliation to Reported EBITDA, see page 17 of this presentat
Slide 15: Gross profit 1H 2019 vs 1H 2018
Gross profit 1H 2019 vs 1H 2018 Reported Revenue vs. gross profit (€m) Commentary ▪ Strong levels of profitability 151.6 ▪ Variation between periods are normal due to phasing of some industrial costs 133.3 ▪ 1H 2019 reduction driven by: 40.1 o Expected price reductions occurring 33.6 in the second s
Slide 16: Operating expenses 1H 2019 vs 1H 2018
Operating expenses 1H 2019 vs 1H 2018 Operating expenses bridge (€m) Commentary % of 62.2% 52.3% 51.9% revenue ▪ Non-recurring expenses of €14.9m: 94.3 o Other Net Expenses/Income include one- 5.2 time stamp duty costs of €5.7m related to 3.5 (14.9) 79.4 the change of ownership structure 2.3% 3.5 o
Slide 17: Adjusted and Normalized EBITDA margin of 31.0%
Adjusted and Normalized EBITDA margin of 31.0% (4) EBITDA bridge (€m) Commentary % of 22.1% 31.0% 32.4% revenue ▪ Adjusted and Normal. EBITDA of €47.0m, corresponding to a margin of 31.0% on 4.9 revenue compared to 32.4% in 1H 2018 (1.4 ) 47.0 ▪ For the Lugano 9th M.O.R.E. Symposium in 5.7 43.2 Apri
Slide 18: 1H 2019 Results - Capital expenditures
1H 2019 Results - Capital expenditures Investments in tangible and intangible assets Commentary (€m) % of 19.3% 25.6% 17.0% revenue 1H 2019: 52.7 • Capex less than 1H 2018 (€8.3m) 2.0 mainly due to: Intangibles 7.9 10.0 o Land & Building, (€15.0m), for new plant in Rancate bought in 2018 1.7 o Instr
Slide 19: 1H 2019 Results – Adjusted and Normalized Cash flow and working capital
1H 2019 Results – Adjusted and Normalized Cash flow (4) and working capital Consolidated cash flow Commentary (€m) 1H 2019 1H 2018 • Reduction in adjusted free cash flow Cash flow from operating activities 14.8 31.2 due to higher investments in instruments in 1H 2019 along with an increase in Cash f
Slide 20: Outlook
Adedacta International Outlook
Slide 21: Priorities 2H 2019
Priorities 2H 2019 ▪ Follow-up on the M.O.R.E. activities of 1H to have a notable impact on 2H sales ▪ Expansion of core joint products in key markets ▪ Increase market penetration in key geographies and innovation in product portfolio to accelerate growth in the knee segment ▪ Continue to drive spi
Slide 22: Outlook: Financial Targets
Outlook: Financial Targets Metric 2019 Target Commentary Revenue growth Mid teens On track / low-end Adjusted EBITDA margin1 32% +/- 100bps On track / low-end Capex ~10-12% of total revenue Above target Change in Net Working Capital ~5-7% of total revenue On track Tax rate ~21% Better than target Di
Slide 23: Key Pillars of Medacta's Growth Strategy
Key Pillars of Medacta’s Growth Strategy Growth of New Product Segments and Continued Technologies Innovation in Established Increase Penetration in Hip and Knee Portfolio 3 Existing A Markets 2 Continued Expansion of Spine 1 Core hip and knee business grew by 9% B Successful Roll-out c.18% (CC) of
Slide 24: Appendix
Adedacta International Appendix
Slide 25: Consolidated financial statements (unaudited)
Consolidated financial statements (unaudited) Profit & loss statement (€m) (€'000) 1H 2019 1H 2018 Revenues 151,638 133,271 Growth (%) 13.8% COGS (40,059) (33,588) Gross profit 111,579 99,683 Margin (%) 73.6% 74.8% R&D expenses (3,502) (2,231) Sales and Marketing expenses (61,566) (51,235) General a